• About us
• Contact

Advertisement

Organisation › Details

Sofinnova Partners SAS

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. *

 

	Start	1997-08-25 established
	Group	Sofinnova (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997)
	Person 2	Lucquin, Denis (Sofinnova Partners 201509 Managing Partner + Chairman)
	Region	Paris
	Country	France
	Street	7–11 Boulevard Haussmann
	City	75009 Paris
	Tel	+33-1-7623-4100
		Address record changed: 2024-01-05
Basic data	Employees	B: 11 to 50 (2020-04-22)
	Currency	EUR
	Annual sales	2,500,000,000 (funds, managed (2023) 2023-12-13)
		* Document for »About Section«: Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris.
		Record changed: 2024-12-18

Advertisement

More documents for Sofinnova (Group)

• [1] Purespring Therapeutics Ltd.. (10/9/24). "Press Release: Purespring Therapeutics Raises £80/$105 Million in a Series B Financing to Transform the Treatment of Kidney Diseases". London....
• [2] Genespire S.r.l.. (9/25/24). "Press Release: Genespire Raises €46.6 Million (~$52 Million) in a Series B Round to Advance Its First Pediatric in-vivo Gene Therapy into the Clinic". Milan....
• [3] Novameat Tech SL. (9/12/24). "Press Release: Novameat Raises €17.4M Oversubscribed Series A Round Led by Sofinnova Partners and Forbion". Barcelona....
• [4] Sofinnova Partners. (9/10/24). "Press Release: Sofinnova Partners Appoints Karl Naegler as Partner". Paris....
• [5] Deepc GmbH. (7/24/24). "Press Release: Deepc Closes Series A Extension to Accelerate Global Deployment of Healthcare AI, Bringing Total Funding to $30m". Munich....
• [6] Endoron Medical Ltd.. (7/9/24). "Press Release: Endoron Medical Raises $10 Million in Series A Funding Led by Sofinnova Partners to Accelerate the Validation of Its AAA EndoStapling Solution Aortoseal". Tel Aviv....
• [7] Marea Therapeutics. (6/18/24). "Press Release: Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases". South San Francisco, CA....
• [8] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
• [9] Bioptimus SAS. (2/20/24). "Press Release: Ex-Google DeepMind and Owkin Scientists Team up to Create Bioptimus to Build the First Universal AI Foundation Model for Biology"....
• [10] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.